Tritonix.ai

News / Taiwan / cnyes

Anbogen Therapeutics Partners with University of Tokyo to Advance ABT-301 Oncology Research

Health Technology · Biotechnology · cnyes · 2026-08-24

7784

Anbogen Therapeutics has signed a research agreement with the University of Tokyo to evaluate the efficacy of ABT-301 in various solid tumor models.

What Happened

Strategic Research Collaboration: Anbogen Therapeutics has entered into a research agreement with the University of Tokyo's Veterinary Surgery Laboratory to evaluate its lead compound, ABT-301 (Imofinostat). The partnership leverages specialized veterinary oncology models to assess the drug's efficacy across a range of solid tumors.

Expanding Clinical Potential: The study focuses on diverse cancer types, including osteosarcoma, melanoma, and soft tissue sarcoma. By utilizing these preclinical models, Anbogen aims to generate robust scientific evidence to support the expansion of ABT-301's indications for future human clinical trials.

Optimizing Combination Therapies: The research will involve comprehensive mechanistic analysis to determine the efficacy of ABT-301 both as a monotherapy and in combination with other agents. These findings are expected to refine future clinical trial designs and identify predictive molecular markers for better patient outcomes.

Advancing Pipeline Development: ABT-301 is currently undergoing Phase 1/2 clinical trials for metastatic colorectal cancer. Anbogen’s leadership emphasized that this collaboration is a key step in systematically evaluating the drug's potential beyond its current focus, aiming to address significant unmet needs in oncology.

Read original

More in Health Technology

Taiho's Antithrombotic Oral Film BEQIA Enters FDA NDA Review Phase

Health Technology · cnyes · 2026-08-24

Taiho announced that its antithrombotic oral film drug BEQIA has officially entered the FDA's substantive NDA review process, with global licensing efforts underway.

6467

FSS to Host Briefing Sessions on Enhanced Disclosure Guidelines for Pharma and Biotech Firms

Health Technology · yonhap_finance · 2026-08-24

The Financial Supervisory Service will hold a series of briefings next month to guide pharmaceutical and biotech companies on new, stricter disclosure requirements.

COVID-19 Diagnostic and Pharmaceutical Stocks Rally Amid Resurgence Concerns

Health Technology · yonhap_finance · 2026-08-24

Shares of COVID-19 diagnostic kit manufacturers and pharmaceutical companies surged in early trading following reports of a sharp rise in infection rates.

019170, 096530, 114450, 253840

Latest in Taiwan

CPC Corporation's Dalin Refinery Fire Extinguished; Fuel Supply Remains Stable

Energy Minerals · cnyes · 2026-08-24

A fire at CPC Corporation's Dalin refinery caused by a pump leak was successfully extinguished with no casualties, and the company confirms fuel supplies remain unaffected.

Lite-On Tech Hits Record High Amid AI Server Momentum Despite Market Volatility

Electronic Technology · economic_daily · 2026-08-24

Lite-On Technology surged to a record high of NT$287, defying broader market weakness, as strong AI server demand and record-high gross margins fueled investor optimism.

Wafer Demand Recovery and Expansion Plans Drive Wafer Works Stock Higher

Electronic Technology · economic_daily · 2026-08-24

Wafer Works shares surged toward the daily limit as the company benefits from a semiconductor market recovery and aggressive 12-inch wafer capacity expansion.

6182

Wafer Price Hikes Propel Formosa Sumco to Daily Limit

Electronic Technology · economic_daily · 2026-08-24

Formosa Sumco shares surged to the daily limit as the semiconductor industry sees a clear trend of rising silicon wafer prices driven by AI-related demand.

3532